Company: IMNN
Filing Date: 2025-06-09
Form Type: DEF 14A
Source: 0001641172-25-014324
Chunk: 39

Company: Imunon, Inc.
Filing Date: 2025-06-09
Form: DEF 14A
Chunk 39
---
1.22 |     | 6/12/2024 |     | 6/12/2034  |     | $         | 1.12 |
|                         |     |                                              | 4,964 |     | $         | 1.04 |     | 9/6/2024  |     | 9/6/2034   |     | $         | 0.99 |

| (1) | Each                                                                                                                              
 of these stock option grants vests with one-half of the grant vesting on the date of grant and one fourth of the grant vesting on 
 each of the first and second anniversary of the date of grant, subject to the applicable director’s continued service as a        
 member of our Board through each applicable vesting date.                                                                         |

| 33 |

During the year ended December 31, 2024, each Non-Employee Director of the Company received annual cash compensation in the amount of $27,450 payable in quarterly installments, and an additional $1,980 for attendance at regular meetings of the Board of Directors and $1,080 for each meeting of a committee of the Board of Directors that was not held in conjunction with a meeting of the Board of Directors. Each Non-Employee director is reimbursed for the out-of-pocket costs of attending meetings of the Board of Directors and of committees of the Board of Directors. In 2024, the Chairman of the Audit Committee received an additional annual cash fee of $12,150 and the Chairman of the Compensation Committee received an additional annual cash fee of $9,450.

Acting on behalf of the Board of Directors, Mr. Fritz also received fees totaling $43,200 in 2024 for his role as a Board Liaison to our Board of Directors. Mr. Fritz’s responsibilities as Board Liaison include the following: (i) serve as an initial sounding board for our management regarding issues, matters, or communications to be brought or potentially to be brought before the Board of Directors; (ii) provide input and feedback to management regarding strategic matters, business matters, major scientific, clinical, collaboration, or corporate development matters, key personnel matters, or other items of significance regarding which management would like to obtain initial or further Board guidance, including, but not limited to, guidance regarding timing and content of communications regarding such matters or items with the full Board or any of its committees; (iii) remain accessible to management to provide guidance on business or strategy issues or other issues of significance on an